



MEDICAMENT

MEDICAL Marijuana rEsearch NewsleTter

WINTER 2019

Welcome to MEDICAMENT,

the Consortium for Medical Marijuana Clinical Outcomes Research's quarterly newsletter!

Established by Florida Statute in June 2019 and officially launched in August 2019, the Consortium for Medical Marijuana Clinical Outcomes Research is composed of public and private universities within the state of Florida engaged in research on clinical outcomes of medical marijuana.

The Consortium, led by the University of Florida and including a total of 9 Florida universities was established by Florida lawmakers to organize a program of research that contributes to the body of scientific knowledge on the effects of the medical use of marijuana and informs both policy and medical practice related to the treatment medical conditions with marijuana.



Consortium for Medical Marijuana Clinical Outcomes Research

To learn more about the Consortium and our programs, visit our new website at mmjoutcomes.org.

2019 MEMBER INSTITUTIONS

From Tallahassee to Miami, academic institutions involved in medical marijuana research have joined the efforts of the Consortium for Medical Marijuana Clinical Outcomes Research.



- 1 FLORIDA STATE UNIVERSITY
- 2 FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY
- 3 UNIVERSITY OF FLORIDA
- 4 UNIVERSITY OF CENTRAL FLORIDA
- 5 FLORIDA ATLANTIC UNIVERSITY
- 6 FLORIDA GULF COAST UNIVERSITY
- 7 FLORIDA MEMORIAL UNIVERSITY
- 8 FLORIDA INTERNATIONAL UNIVERSITY
- 9 UNIVERSITY OF MIAMI

THE CONSORTIUM CONCENTRATES EFFORTS INTO 3 FOCUS AREAS:

- 1 **RESEARCH GRANTS PROGRAM**
Organize a competitive grants program for Consortium member institutions to fund research projects across Florida.
- 2 **CLINICAL CORE**
Provide infrastructure to support clinical research of medical marijuana outcomes throughout the state.
- 3 **MEMORY DATA REPOSITORY**
Create a data repository that allows tracking of real-world outcomes and safety surveillance of medical marijuana use.

\$600K+
research
grant dollars

41
research
grant
applications

10
research
projects
funded

RESEARCH STRATEGY UPDATES

2019 GRANTS PROGRAM

The Consortium for Medical Marijuana Clinical Outcomes Research supports clinical and translational research related to medical marijuana across the state of Florida through the Consortium MMJ Clinical Outcomes Research Grants Program.

Faculty at the Consortium member institutions submit research proposals in response to an annual request for applications (RFA) to compete for research funding by the Consortium. The funding serves to support research that can further our understanding of the clinical use of marijuana for treatment of a variety of conditions.

This fall, the Consortium received 41 grant applications from researchers and faculty and agreed to fund 10 applications including projects from the University of Miami, the University of Florida, Florida A&M University, Florida Gulf Coast University, and Florida Atlantic University.

To learn more about the Consortium MMJ Clinical Outcomes Research Grants Program, visit our website:
<https://mmjoutcomes.org/grants-program/>

2020 GRANTS PROGRAM

In early 2020, the Consortium for Medical Marijuana Clinical Outcomes Research will start the next funding cycle of the Consortium MMJ Clinical Outcomes Research Grants Program.

More details about the 2020 Grants Program coming next issue of MEDICAMENT.

CLINICAL CORE UPDATES

COLLABORATION EFFORTS

The Clinical Core serves to connect potential medical marijuana industry and business partners to researchers and to connect researchers to the broad range of services and support infrastructure made available by the Clinical and Translational Science Institutes (CTSIs) across the state of Florida. Infrastructure can include assistance with recruitment, data collection, or access to laboratory experts.

In spring 2020, the Consortium will conduct its first annual provider survey to help shape the Consortium's research agenda. Central to the survey will be questions about specific research needs to help clinical decision-making when treating patients with medical marijuana.

More details about the Annual Provider Survey coming next issue of MEDICAMENT.

AMMPA 2019

From October 4 through October 6, 2019, members of the Consortium for Medical Marijuana Clinical Outcomes Research Team attended and hosted an exhibit at the American Medical Marijuana Physicians Association (AMMPA) Annual Conference in Orlando, Florida.

The Consortium networked with physicians, medical marijuana dispensary workers, scientists, and others interested in medical marijuana.

At the conference, the Consortium distributed and collected important information from providers including perceived research priorities related to medical marijuana use. Insights collected from providers will help shape the future research agenda for the Consortium.



From left to right: Jennifer Jean- Jacques, Yan Wang, Ph.D., Robert Cook, M.D., M.P.H., and Sebastian Jugl

To learn more about the Consortium's participation in the 2019 AMMPA Annual Conference, visit our website: <https://mmjoutcomes.org/2019-ammipa/>

MEMORY UPDATES

ABOUT MEMORY

The MMJ Clinical Outcomes Research Data Repository (MEMORY) will establish the infrastructure for real-world MMJ clinical outcomes evaluations.

The Consortium aims to link the Office of Medical Marijuana Use (OMMU) MMJ dispensing data with other clinical databases commonly used for outcomes research to create a robust research-ready repository.

The planned linkages will join information on MMJ use (type, dose, route, originating plan from the OMMU registry) and on patient health history, other treatments and outcomes (from linked clinical encounter data), and facilitate controlled longitudinal studies on safety and effectiveness outcomes.

Currently, the Consortium is collaborating with the Florida Department of Health to launch MEMORY.

CONSORTIUM BOARD MEMBERS



From left to right: Robert Cook, M.D., M.P.H. (Consortium Associate Director), W. Dalton Dietrich, Ph.D., Cynthia Hughes Harris, Ph.D., OTR, FAOTA, FASAHP, Martha D. Rosenthal, Ph.D., Roger B. Fillingim, Ph.D. (Board Chair), Daniel C. Flynn, Ph.D. (Board Vice Chair), Almut G. Winterstein (Consortium Director), and Timothy A. Gilbertson, Ph.D. not pictured: William Anderson, Ph.D., Max C. E. Orezza, Ph.D., and Eric H. Holmes, Ph.D.

Each member institution of the Consortium for Medical Marijuana Clinical Outcomes Research has provided one representative for the Consortium Board of Directors, which had its inaugural meeting in August 2019.

On the 19th of August, the Consortium Board met for the first time to discuss the Consortium mission, adopt the charter and bylaws, appoint Consortium leadership, and review the research plan and budget. Board members from six member institutions attended the daylong meeting at the University of Florida.

To learn more about board meetings, visit our website: <https://mmjoutcomes.org/board-meetings/>

CONSORTIUM LEADERSHIP TEAM



ALMUT G. WINTERSTEIN,
R.Ph., Ph.D., FISPE
Consortium Director



ROBERT L. COOK,
M.D., M.P.H.
Consortium
Associate Director



AMIE GOODIN,
Ph.D, MPP
Faculty Lead
Research Strategy



JUAN HINCAPIE-CASTILLO,
Pharm.D., M.S., Ph.D.
Faculty Lead
MEMORY



YAN WANG, Ph.D.
Faculty Lead
Clinical Core

To read more about the Consortium Leadership, visit our website: <https://mmjoutcomes.org/leadership/>

COMING NEXT ISSUE:

- Results from a statewide provider survey
- Details on funded grants for 2019-20
- Announcements about the 2020-21 grants program

DON'T WANT TO MISS ANY MEDICAMENT ISSUES?

To sign up for the quarterly MEDICAMENT issues from the Consortium for Medical Marijuana Clinical Outcomes Research, sign up here: mmjoutcomes.org/newsletter/